Backwater to mainstream: science and tech legends transformed Cambridge
Acorn Computers was marooned up a murky creek struggling to locate a paddle; founders of a fledgling Arm were desperate to jump ship. The situation could have escalated into a technology Titanic – a brave new world sinking in a battered heap.
Instead, Arm ended up a titan and sailed on to bright new horizons – and even saved the mother ship, Acorn.
Cambridge technology entrepreneur Stan Boland – then at the epicentre as the foundations rocked and rumbled – relives the rescue saga with a warts and all assessment in Business Weekly’s iconic 30th Anniversary edition out this week.
In a definitive review of Cambridge’s transition from cabbage patch in 1990 to billionaire’s row in 2020 – with science and technology driving the transformation – Boland also goes under the hood of his other tech companies, recalling the bruises as well as the brilliance.
Sir Christopher Evans, founding father of the Cambridge biotechnology cluster, is equally frank about the fight for funding that took him and others first to the City and then to global investors to ensure brilliant life science research cultivated on Cambridge’s doorstep did not wither on the vine. Now Cambridge is one of the world’s leading life science hubs.
Relive the post 9/11 fall-out in the ‘special relationship’ as the White House bought a Cambridge smallpox vaccine to fight the perceived threat of biological warfare while Britain gave its contract to a Labour donor – and was accused of using the wrong strain in the vaccine and putting the UK population at risk.
As well as charting the major corporate events over the 30 years that Business Weekly has promoted this region to a global audience, our Anniversary edition demonstrates how much other countries and governments have come to rely on Cambridge science & technology to solve critical problems.
Read how US defence chiefs have turned to Cambridge technology to eradicate weaknesses in integrated circuit chips – a vulnerability that threatens economic and national security.
How world governments have turned to Cambridge Big Biotech and pharma players to lead the fight against coronavirus: How Cambridge cluster companies are changing the core paradigm of the international life science industry.
And as Business Weekly continues to dictate the news agenda, read about the commercialisation of the world’s first flying car; major new fundraisings and financial innovation; how former Home Secretary Amber Rudd has joined the advisory board of cyber security world leader Darktrace; and FFI’s new $1m conservation project steered from Cambridge with global funding to help counter another aspect of the COVID-19 fall-out.
Throughout our 30-year history, Business Weekly has piled exclusive upon exclusive and we lead our Anniversary edition with another great insight on a company poised to make a difference to healthcare for decades to come.
Co-steered by brilliant former CAT and MedImmuine (AstraZeneca) scientist Jane Osbourn, Alchemab flips the coin of life science research and unveils a platform that focuses not on why so many people become ill but why increasing numbers stay well for longer – increasingly past the age of 100.
The ageing well! More Cambridge innovation; and this backed by an alliance with genomic sequencing ace Illumina.
Alchemab is yet another One2Watch for investors and business builders brought to you exclusively by Business Weekly.